Medscape

FDA Approves Selpercatinib for Lung and Thyroid RET Tumors

Selpercatinib (Retevmo, Loxo/Lilly) becomes the first targeted therapy to be approved by the US Food and Drug Administration (FDA) for use in patients with cancer who have certain tumors that have an ...
Cure Today

Retevmo Improves RET-Mutant Thyroid Cancer Outcomes

Progression-free survival improved with Retevmo as the initial treatment for patients with advanced RET-mutant medullary thyroid cancer. Retevmo (selpercatinib) improved progression-free survival ...
FierceBiotech

ESMO: Lilly's RET drug shrinks more than half of rare thyroid cancers

The RET inhibitor Eli Lilly picked up in its Loxo Oncology buyout continues to deliver. On the heels of an encouraging performance in lung cancer, the drug shrank tumors in more than half of patients ...
Medscape

RET Mutation in Medullary Thyroid Cancer Predicts Worse Survival

October 18, 2007 — Patients with medullary thyroid carcinoma (MTC) who have a somatic RET mutation have a worse outcome and a significantly lower survival rate than those without this mutation. While ...
Nasdaq

Roche announces FDA approval of Gavreto (pralsetinib) for people with advanced or metastatic RET-mutant and RET fusion-positive thyroid cancers

Basel, 2 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved Gavreto™ (pralsetinib) for the treatment of adult and ...
Nasdaq

Blueprint Medicines Announces Submission of New Drug Application to FDA for Pralsetinib for the Treatment of Advanced RET Mutant and RET Fusion-Positive Thyroid Cancers

CAMBRIDGE, Mass., July 1, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer ...
MedPage Today

RET Fusion Inhibitor Active Beyond Lung, Thyroid Cancers

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The RET ...
Monthly Prescribing Reference

Retevmo Gets Accelerated Approval for RET-Driven Lung, Thyroid Cancers

The FDA has granted accelerated approval to Retevmo™ (selpercatinib; Lilly). The Food and Drug Administration (FDA) has granted accelerated approval to Retevmo™ (selpercatinib; Lilly), a selective RET ...
Seeking Alpha

The China NMPA Approves Selpercatinib for the Treatment of Patients with RET-driven Lung and Thyroid Cancers

ROCKVILLE, Md. and SUZHOU, China , Oct. 9, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (IVBIY) ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...
MedPage Today

RET Inhibitor Posts Frontline Wins in Medullary Thyroid Cancer, NSCLC

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window MADRID -- ...
Business Insider

Lilly Receives U.S. FDA Approval for Retevmo™ (selpercatinib), the First Therapy Specifically for Patients with Advanced RET-Driven Lung and Thyroid Cancers

Retevmo was granted orphan drug designation by the FDA for the treatment of RET fusion-positive NSCLC and for the treatment of RET fusion-positive and RET -mutant thyroid cancers including poorly ...
Business Wire

Genentech Announces FDA Approval of Gavreto (pralsetinib) for People With Advanced or Metastatic RET-Mutant and RET Fusion-Positive Thyroid Cancers

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved ...